# Paragraf acquires Cardea Bio

Paragraf, Ltd. acquired Cardea Bio, the developer of the CRISPR-Chip graphene-based biosensor. The acquisition combines Paragraf's mass production of graphene electronics with Cardea's biosensor expertise to support CRISPR QC's gene editing analytics platform.

- Type: Acquisition
- Announced: 2023-05-03
- Where: San Diego, California, United States
- Status: completed
- Products: graphene-based biosensors, CRISPR-Chip
- Sectors: [Semiconductors and Industrial Electronics](https://endata.com/sectors/semiconductors-electronics.md)

## Companies

- [Cardea Bio](https://endata.com/companies/42804.md) (target)
- [Paragraf](https://endata.com/companies/70096.md) (acquirer)

## Sources

- [businesswire.com](https://www.businesswire.com/news/home/20230503005191/en/Paragraf-Acquires-CRISPR-Chip-Developer-Cardea-Bio-Accelerating-CRISPR-QCs-Business-Opportunity), 2023-05-03: "We are excited to see Cardea merge into the Paragraf family."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.